{"filing":{"accession_number":"0001437749-26-026428","cik":"0001719406","ticker":"NRXPW","company_name":"NRX Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"nrxp20260806_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1719406/000143774926026428/nrxp20260806_8k.htm"},"events":[{"id":26185,"run_id":23782,"accession_number":"0001437749-26-026428","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure reports FDA feedback on an ANDA for preservative-free ketamine, including a first-round review with no drug-related major deficiencies but one packaging-related deficiency requiring clarification. The FDA has committed to expedited review given ketamine's status on the drug shortage list and strategic importance. This is a material regulatory milestone affecting the company's path to commercialization, but does not fit the specific categories of restatement, auditor change, going concern, impairment, litigation, or other named event types. It is clearly operational/regulatory in nature—a product development and regulatory approval milestone.","company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXPW","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27216,"accession_number":"0001437749-26-026428","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports FDA feedback on an ANDA for preservative-free ketamine, including a first-round review with no drug-related major deficiencies but one packaging-related deficiency requiring clarification. The FDA has committed to expedited review given ketamine's status on the drug shortage list and strategic importance. This is a material regulatory milestone affecting the company's path to commercialization, but does not fit the specific categories of restatement, auditor change, going concern, impairment, litigation, or other named event types. It is clearly operational/regulatory in nature—a product development and regulatory approval milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T02:15:14.037955+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27216,"accession_number":"0001437749-26-026428","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports FDA feedback on an ANDA for preservative-free ketamine, including a first-round review with no drug-related major deficiencies but one packaging-related deficiency requiring clarification. The FDA has committed to expedited review given ketamine's status on the drug shortage list and strategic importance. This is a material regulatory milestone affecting the company's path to commercialization, but does not fit the specific categories of restatement, auditor change, going concern, impairment, litigation, or other named event types. It is clearly operational/regulatory in nature—a product development and regulatory approval milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T02:15:14.037955+00:00","company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXPW","filing_date":"2026-08-07"}]}